(Q53339170)
Statements
Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. (English)
1 reference
van Dyck CH
1 reference
Newhouse P
1 reference
Falk WE
1 reference
Mattes JA
1 reference
1 February 2000
1 reference
57
1 reference
2
1 reference
157-164
1 reference
Identifiers
1 reference